Article
MEN1 mutations mediate clinical resistance to menin inhibition.
Nature - 1 Mar 2023
Perner Florian, Stein Eytan M, Wenge Daniela V, Singh Sukrit, Kim Jeonghyeon, Apazidis Athina, Rahnamoun Homa, Anand Disha, Marinaccio Christian, Hatton Charlie, Wen Yanhe, Stone Richard M, Schaller David, Mowla Shoron, Xiao Wenbin, Gamlen Holly A, Stonestrom Aaron J, Persaud Sonali, Ener Elizabeth, Cutler Jevon A, Doench John G, McGeehan Gerard M, Volkamer Andrea, Chodera John D, Nowak Radosław P, Fischer Eric S, Levine Ross L, Armstrong Scott A, Cai Sheng F
Abstract excerpt
Chromatin-binding proteins are critical regulators of cell state in haematopoiesis1,2. Acute leukaemias driven by rearrangement of the mixed lineage leukaemia 1 gene (KMT2Ar) or mutation of the nucleophosmin gene (NPM1) require the chromatin adapter protein menin, encoded by the MEN1 gene, to sustain aberrant leukaemogenic gene expression programs3-5. In a phase 1 first-in-human clinical trial, the menin...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.